News · Heart & Metabolic
Carrying one copy of the alpha-1 antitrypsin variant raised liver risk, not just two
Single-copy carriers are usually told they are unaffected. Following 22,537 genotyped veterans for a median of 15.9 years found risk rising step by step with each copy of the variant.
- Risk of serious liver outcomes rose with each copy of the Z variant carried.
- Single-copy carriers, usually considered unaffected, carried measurably higher risk.
- Two copies roughly doubled the five-year risk against no copies.
- Liver cancer specifically was raised only in those with two copies.
- A veterans cohort followed a median of 15.9 years, so the group is mostly male.
Genetic counseling has a comfortable category called the carrier: someone with one copy of a harmful variant, who passes it on but is not expected to suffer from it themselves.
For alpha-1 antitrypsin deficiency that reassurance has been standard. Two copies of the Z variant cause lung and liver disease. One copy has generally been filed as a fact about your children rather than about you.
How 22,537 alpha-1 genotyped veterans were followed
Writing in Hepatology, researchers used a national cohort of veterans whose alpha-1 genotype had already been tested for clinical reasons, and tracked what happened to their livers.
That produced 22,537 participants with genotype testing and more than 350,000 person-years of follow-up, over a median of nearly sixteen years. Previously the liver risk in single-copy carriers had been debated on smaller and shorter studies.
They counted major adverse liver outcomes: the liver failing, cancer developing, transplantation, or death from liver disease.
How liver risk rose with each Z copy carried
Risk did not divide into affected and unaffected. It climbed with each copy.
Against people with no Z variant, single-copy carriers ran about a quarter higher. Those with the intermediate combination ran about half again higher. Those with two copies ran about 80% higher.
In absolute terms the five-year probability of a serious liver outcome went from about 3.5% with no variant to about 5.5% with one copy and about 8% with two.
A dose-response like that is one of the stronger patterns in observational work. Chance and confounding can produce a difference between two groups; producing an orderly progression across four is harder.
Why single copies raised scarring but not liver cancer
The two groups did not simply differ in degree.
People with two copies had raised risk of every component, liver cancer included. Single-copy and intermediate carriers had raised risk of scarring, transplantation and liver-related death, but not of liver cancer.
That split is informative. It suggests carrier risk runs through accumulated liver injury rather than through whatever pathway produces tumors, which is a different biological story and points at different monitoring.
Why one in 25 people carrying a copy matters
Alpha-1 antitrypsin deficiency is an inherited condition that can cause lung and liver disease, and the full two-copy form is rare.
Single copies are not. Roughly one in 25 people of European ancestry carries one. A quarter-increase in risk changes little for an individual and shifts a substantial number of liver outcomes across a population that size.
What a veterans cohort cannot settle about screening
These were veterans, overwhelmingly male, and tested because a clinician had a reason to test them. That is not the general population, and people get genotyped when something has already prompted the question.
The analysis adjusts for what was recorded and cannot adjust for what was not: alcohol history in particular is the obvious companion to liver injury, and a check restricted to patients with fatty liver disease pointed the same way without resolving it.
And nobody here was screened. The study describes risk among people whose genotype was already known, which is exactly the group the authors say deserves closer surveillance, and says nothing about testing everybody.
What a carrier should be told about their liver
A conversation that currently ends too early. Someone told they are a carrier is told, correctly, that they will not develop the full condition, and then usually told nothing else.
On this evidence the right addition is modest and concrete: the liver is worth watching, and the things that compound liver injury, alcohol and excess weight above all, matter more for a carrier than for someone with two normal copies.
People also ask
What did the study find?
Among 22,537 participants (19,665 Pi*MM, 1,656 Pi*MZ, 281 Pi*SZ, 935 Pi*ZZ), risk of major adverse liver outcomes rose with allele burden against Pi*MM: Pi*MZ adjusted hazard ratio 1.25 (1.11-1.40), Pi*SZ 1.51 (1.17-1.94), Pi*ZZ 1.80 (1.57-2.07). Five-year probability was 3.5%, 5.5%, 5.3% and 8.1% respectively. Pi*ZZ raised all components including liver cancer; Pi*MZ and Pi*SZ raised decompensation, transplantation and liver-related death but not cancer.
What is alpha-1 antitrypsin deficiency?
An inherited condition in which the liver makes a faulty version of a protein that normally protects the lungs. The faulty protein can accumulate in liver cells and damage them, while its absence elsewhere leaves the lungs vulnerable.
What do the genotype labels mean?
M is the normal version of the gene, Z the most damaging variant and S an intermediate one. Everyone carries two copies, so Pi*MM means no variant, Pi*MZ one Z copy, and Pi*ZZ two.
How common is carrying one copy?
Roughly one in 25 people of European ancestry carries a single Z copy. That is why a modest increase in risk among carriers matters at population scale even though it changes little for any one person.
Why does the liver cancer result differ?
Only the two-copy group showed raised liver cancer risk, while single and intermediate carriers showed raised scarring, transplantation and liver-related death without it. That pattern suggests carrier risk runs through cumulative liver injury rather than through the route that produces cancer.
Does this mean carriers should be tested or monitored?
The authors argue for timely diagnosis and closer surveillance among people whose genotype is already known. It does not establish that population screening would help, which is a different question requiring different evidence.
What should a carrier do?
Alcohol and excess weight both compound liver injury, and someone who knows they carry the variant has particular reason to take that seriously. Monitoring decisions belong with a clinician. This is general information rather than medical advice.